The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Insights into the use of purinostat mesylate in R/R DLBCL
Lijuan Chen, MD, PhD, West China Hospital, Sichuan University, Chengdu, China, shares insights into the potential of purinostat mesylate (PM), a potent HDAC inhibitor, in treating various cancers, including relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and solid tumors. Dr Chen highlights that PM has shown promising results as a monotherapy in Phase I and IIa trials for R/R DLBCL, and is now moving forward with Phase III registration in China. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
